Published • loading... • Updated
WuXi XDC Achieves GMP Release of BCM3 Facility at Singapore Site, Enabling Global Clients with Professional Excellence
- WuXi XDC Cayman Inc. announced its BCM3 production line in Singapore has achieved GMP release for antibody intermediates and drug substances of bioconjugates.
- This GMP release marks a new phase in WuXi XDC's global capacity expansion to help clients accelerate commercial manufacturing with efficiency and flexibility.
- The BCM3 facility is WuXi XDC's first overseas GMP-approved site, featuring a dual-function design that offers integrated end-to-end manufacturing services from antibody intermediates to conjugated drugs.
- WuXi XDC completed the design to GMP release process of BCM3 in two and a half years, demonstrating their rapid development approach known as 'WuXi Speed'.
Insights by Ground AI
19 Articles
19 Articles
Bennington Banner+18 Reposted by 18 other sources
WuXi XDC Achieves GMP Release of BCM3 Facility at Singapore Site, Enabling Global Clients with Professional Excellence
SINGAPORE, Aug. 18, 2026 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today announced that its BCM3 dual-function production line for antibody…
Coverage Details
Total News Sources19
Leaning Left2Leaning Right2Center12Last UpdatedBias Distribution75% Center
Bias Distribution
- 75% of the sources are Center
75% Center
13%
C 75%
12%
Factuality
To view factuality data please Upgrade to Premium
